一名患有罕见神经疾病的澳大利亚妇女,尽管已经证明有益处,但在其他几个国家却得不到补贴的亚皮层免疫球蛋白治疗。 An Australian woman with a rare nerve disease is denied subsidized subcutaneous immunoglobulin therapy available in several other countries, despite proven benefits.

澳大利亚的一位罕见的病人27年前被诊断患有多功能运动神经病, 表示她被剥夺了获得皮下免疫球蛋白(SCIg)治疗(SCIg)的机会——这是在英国、加拿大、法国和意大利已经证明的、更安全、更方便的治疗方法。 A rare disease patient in Australia, diagnosed with multifocal motor neuropathy 27 years ago, says she is denied access to subcutaneous immunoglobulin (SCIg) therapy—a proven, safer, and more convenient treatment available in the UK, Canada, France, and Italy. 尽管有证据表明SCIG改善了生活质量,减少了就诊次数,降低了医疗费用,但在澳大利亚,由于她的罕见状况,它仍然没有资金,影响到大约600人。 Despite evidence showing SCIg improves quality of life, reduces hospital visits, and lowers healthcare costs, it remains unfunded in Australia for her rare condition, affecting about 600 people. 她继续忍受频繁、破坏性的静脉注射,而倡导者则敦促政府对现有研究采取行动,扩大获得现有疗法的机会。 She continues to endure frequent, disruptive intravenous infusions, while advocates urge the government to act on existing research and expand access to the already-available therapy.